Back to search results

PAS-004 in Patients With Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

RAS Mutation · NF1 Mutation · RAF Mutation · Advanced Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • NEXT Oncology, Austin, Texas, United States

  • NEXT Oncology, Irving, Texas, United States

  • NEXT Oncology, San Antonio, Texas, United States

  • NEXT Oncology, Fairfax, Virginia, United States

  • MBAL Sveta Sofia, Sofia, Bulgaria

    Contact: Study coordinator (Veronika Shopova) · veronika.shopova@arensia-em.com · +359-878-33-4932
    Contact: Principal Investigator (Marchela Koleva)

  • Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania

    Contact: Study coordinator (Natalia E. Cojocaru) · natalia.cojocaru@arensia-em.com · +40-783-225-184
    Contact: Principal Investigator (Laurentia Nicoleta Gales)

  • Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania

    Contact: Study coordinator (Adriana Badau) · adriana.badau@arensia-em.com · +40-786-042-357
    Contact: Principal Investigator (Tudor Eliade Ciuleanu)
Study leads

  • Tiago R Marques, MD

    Study Director

    Pasithea Therapeutics Corp.

View source on ClinicalTrials.gov(opens in a new tab)